Synthesis and pharmacological characterization of UVI3502, a novel cannabinoid receptor 1 (CB1) antagonist/inverse agonist

Author:

de Tena Iker BengoetxeaORCID,Pereira-Castelo GorkaORCID,Martínez-Gardeazabal JonatanORCID,Moreno-Rodríguez MartaORCID,Manuel IvánORCID,Martínez ClaudioORCID,Vaz BelénORCID,González-Ricarte JavierORCID,Álvarez RosanaORCID,Torres-Mozas AngelORCID,Peccati FrancescaORCID,Jiménez-Osés GonzaloORCID,De Lera Ángel RodríguezORCID,Rodríguez-Puertas RafaelORCID

Abstract

AbstractThe endocannabinoid (eCB) system regulates several brain functions and is implicated in neurological disorders. The pharmacological blockade of cannabinoid receptors has a therapeutic potential for various cognitive deficits, but also produces severe psychiatric side effects. Hence, new cannabinoid compounds that potentiate therapeutic effects, while minimizing toxicity, are required. In this study, we synthesized and characterized a novel antagonist/inverse agonist of CB1receptors. UVI3502 showed affinity for two [3H]CP55,940 binding sites (IC50Hi0.47 ± 1.94 nM and IC50Lo1470 ± 1.80 nM). Subsequent binding assays performed in CB1and CB2overexpressing membranes determined that the low affinity binding site corresponded to CB1, but the high-affinity binding site of UVI3502 did not correspond to CB2and the possibility of it corresponding to GPR55 was analyzed. The affinity of UVI3502 for CB1receptors was further confirmed with neuroanatomical specificity by autoradiography in key brain areas, in which functional [35S]GTPɣS assays demonstrated that UVI3502 behaved as an antagonist/inverse agonist of CB1receptors, blocking the stimulation evoked by potent cannabinoid receptor agonist CP55,940 and decreasing basal [35S]GTPɣS binding. Thein silicocharacterization of the binding to CB1receptor through molecular docking and molecular dynamics suggests that this activity is explained by the planar and rigid structure of UVI3502, which is optimal for interactions with the inactive state of the receptor. These results indicate that UVI3502 is a novel antagonist/inverse agonist of CB1receptors, making it a compelling candidate for pharmacologically blocking cannabinoid receptors in the central nervous system.Significance StatementUVI3502 is a novel antagonist/inverse agonist of CB1receptors, with almost no affinity for CB2receptors and an additional high-affinity binding site for a third, cannabinoid-like receptor, potentially GPR55. In relevant brain areas for learning and memory processes with a high expression of CB1, UVI3502 blocks the stimulation evoked by the cannabinoid receptor agonist CP55,940, rendering it as an interesting compound for the pharmacological blockade of cannabinoid receptors in the central nervous system.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3